Instil Bio, Inc.
NASDAQ:TILBiotechnology
+$0.01 today
- Market cap
- $50.53M
- Beta
- 1.91
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$6.99
Volume 0.02M
Average 0.03M
TIL Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Instil Bio, Inc.NASDAQ: TIL
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow outflow shrinks to $0
Q1 FY2026 financing cash flow was $0, compared with $232K a year earlier. Trailing-twelve-month financing cash flow was $7.06M. Over 3 fiscal years it compounded at -53.4% a year.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.77M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 7.29M USD
- Year-over-year change
- +315.5%
- 4-year CAGR
- -63.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.29M | +315.5% |
| FY2024 | 2024-12-31 | 1.76M | -78.3% |
| FY2023 | 2023-12-31 | 8.08M | -88.8% |
| FY2022 | 2022-12-31 | 71.89M | -81.7% |
| FY2021 | 2021-12-31 | 393.16M | — |
Financing Cash Flow vs competitors
How TIL compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +255.3% is the 4th highest of 9, against a peer median of +28.5%.
- Over three fiscal years its annual growth of -53.4% compares with a peer median of +154.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $94.38M USD | +72496.9% | +9.1% | 1320.9% |
| LTM Mar 2026 | $70.43M USD | +7606.1% | +538.8% | 7043.4% | |
| LTM Mar 2026 | $69.59M USD | +16083.5% | +247.3% | 44.3% | |
| LTM Mar 2026 | $38.95M USD | -57.9% | — | 519.7% | |
| LTM Mar 2026 | $32.12M USD | -1858.1% | — | — | |
| LTM Mar 2026 | CA$23.71M CAD | +114.9% | +16.7% | — | |
| LTM Mar 2026 | $7.06M USD | +255.3% | -53.4% | — | |
| LTM Mar 2026 | €6.23M EUR | -77.3% | +154.7% | 21245.3% | |
| LTM Mar 2026 | $5.59M USD | -2029.0% | — | — | |
| Peer median (excluding TIL) | — | +28.5% | +154.7% | 1320.9% | |
Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (156.79M) | (223.18M) | (156.09M) | (74.14M) | (71.37M) |
| Depreciation & Amortization | 2.75M | 5.99M | 4.76M | 3.61M | 534K |
| Deferred Income Tax | 710K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 26.2M | 30.44M | 18.17M | 17.26M | 8.69M |
| Change in Working Capital | 4.36M | (9.57M) | (9.02M) | (12.61M) | (560K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (3.4M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.86M | (1.81M) | (1.13M) | (556K) | 116K |
| Other Working Capital | 499K | (7.76M) | (7.89M) | (12.05M) | 2.72M |
| Other Non-Cash Items | 636K | 16.15M | 60.15M | 10.18M | 26.09M |
| Operating Cash Flow | (122.14M) | (180.16M) | (82.03M) | (55.7M) | (36.62M) |
| Capital Expenditures | (57.83M) | (84.59M) | (20.66M) | (10M) | 0 |
| Acquisitions (Net) | 0 | 1.17M | 0 | 0 | 432K |
| Purchases of Investments | (1.11B) | (666.22M) | (301.47M) | (135.6M) | (100.86M) |
| Sales of Investments | 691M | 865.35M | 361.7M | 198.71M | 135.9M |
| Other Investing Activities | 0 | (1.17M) | 1.56M | 866K | 0 |
| Investing Cash Flow | (474.4M) | 114.54M | 41.13M | 53.97M | 25.48M |
| Debt Repayment | 0 | 70.34M | 8.08M | 2.76M | 6.61M |
| Common Stock Issued | 339.02M | 1.55M | 0 | 0 | 853K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.69M | 0 | 0 | (1.01M) | (172K) |
| Financing Cash Flow | 393.16M | 71.89M | 8.08M | 1.76M | 7.29M |
| Effect of Forex Changes | (304K) | (637K) | (201K) | (94K) | 20K |
| Net Change in Cash | (203.67M) | 5.63M | (33.02M) | (61K) | (3.83M) |
| Free Cash Flow | (179.97M) | (264.75M) | (102.69M) | (65.7M) | (36.62M) |
Instil Bio, Inc.
NASDAQ:TIL
Intrinsic Alpha fair value
Locked
Current Price
$7.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.